]>

Table 1: Targeted therapies currently in clinical trial development for MTC.

Drug Target Mechanism of action Zactima (ZD6474) VEGFR, RET, EGFR (HER1) Tyrosine kinase inhibitor XL184 VEGFR2, MET, RET Tyrosine kinase inhibitor Imatinib (STI571) bcr-abl, PDGFR, C-KIT Tyrosine kinase inhibitor Sorafinib (BAY-43-9006) BRAF, CRAF, VEGFR, RET, PDGFR Tyrosine kinase inhibitor Sunitinib (SU11248) VEGFR, RET, PDGFR, C-KIT, CSF-1R, flt3 Tyrosine kinase inhibitor AMG-706 VEGFR1-3, PDGFR, C-KIT Tyrosine kinase inhibitor Gefitinib EGFR (HER1) Tyrosine kinase inhibitor Axitinib (AG-013736) VEGFR, PDGFR, C-KIT Tyrosine kinase inhibitor Pazopanib (GW786034) VEGFR1-3, PDGFR, C-KIT Tyrosine kinase inhibitor SAHA Notch1, TNF-α, IL-1-β, IL-6, IFN-γ HDAC inhibitor Lithium GSK-3ß Unknown, suspected GSK3 inhibition, inositol depletion